Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Show more
Location: 2525 East North Carolina Highway 54, Durham, NC, 27713, United States | Website: https://humacyte.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
231.2M
52 Wk Range
$1.15 - $6.77
Previous Close
$1.46
Open
$1.45
Volume
1,771,503
Day Range
$1.41 - $1.46
Enterprise Value
208.3M
Cash
38.03M
Avg Qtr Burn
-26.12M
Insider Ownership
19.74%
Institutional Own.
36.37%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Details Dialysis access (AV access) | BLA Submission |